The establishment of a metastatic renal cell carcinoma (mRCC) cell line can facilitate the search for molecular mechanisms involved in RCC metastasis. A novel human mRCC cell line, designated RCC96, was established from an mRCC of the spine from a 65-year-old Chinese man. Morphology, cell cycle phase, chromosome number, cell capability of migration, tumorigenicity in nude mice, and cytogenetic features of RCC96 were investigated. Cell growth curve was detected and the cell number doubling time was 52 h. Karyotype analysis showed that these cells were polyploidy. Transmission electron microscope showed that cells were with large atypical nuclei, well-developed rough endoplasmic reticulum, rich Golgi complex, and mitochondria, as well as visible microacinar in the cytoplasm. PCR and immunofluorescence staining demonstrated that the expression of some genes such as KISS-1, MMP2, and VEGF in RCC96 was not entirely consistent with that in other RCC cell lines, indicating the differences between primary and metastatic RCC cell lines. The RCC96 cell line may serve as a useful tool for studying the molecular pathogenesis and testing new therapeutic reagents for mRCC.
Get full access to this article
View all access options for this article.
References
1.
AlthausenP., AlthausenA., JenningsL.C., and MankinH.J. (1997). Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer, 80, 1103–1109.
2.
AveryA.K., BecksteadJ., RenshawA.A., and CorlessC.L. (2000). Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol, 24, 203–210.
3.
BohmP., and HuberJ. (2002). The surgical treatment of bony metastases of the spine and limbs. J Bone Joint Surg Br, 84, 521–529.
4.
ChenS., ChenW., ZhangX., LinS., and ChenZ. (2016). Overexpression of KiSS-1 reduces colorectal cancer cell invasion by downregulating MMP-9 via blocking PI3K/Akt/NF-kappaB signal pathway. Int J Oncol, 48, 1391–1398.
5.
ChuP., and ArberD.A. (2000). Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol, 113, 374–382.
6.
DabestaniS., MarconiL., and BexA. (2016). Metastasis therapies for renal cancer. Curr Opin Urol, 26, 566–572.
7.
DaiL., LuX.H., LiZ.H., LiR., LiuH., LiuY.L., et al. (2004). Value of special stains and immunohistochemistry in the diagnosis of renal epithelial neoplasms. Zhonghua Bing Li Xue Za Zhi, 33, 140–142.
8.
DharD.K., NaoraH., KubotaH., MaruyamaR., YoshimuraH., TonomotoY., et al. (2004). Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int J Cancer, 111, 868–872.
9.
FoghJ. (1978). Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr (49):5–9.
10.
FoghJ., WrightW.C., and LovelessJ.D. (1977). Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst, 58, 209–214.
11.
GnarraJ.R., ToryK., WengY., SchmidtL., WeiM.H., LiH., et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet, 7, 85–90.
12.
HanS., WangT., JiangD., YuY., WangY., YanW., et al. (2015). Surgery and survival outcomes of 30 patients with neurological deficit due to clear cell renal cell carcinoma spinal metastases. Eur Spine J, 24, 1786–1791.
13.
HasegawaS., KatoK., TakashiM., ZhuY.Y., YokoiK., KobayashiH., et al. (1991). S100a0 protein and creatine kinase isozymes (CK-B & CK-M) in serum and urine might be useful markers for non specific tissue damages by extracorporeal shockwave lithotripsy (ESWL). Nihon Hinyokika Gakkai Zasshi, 82, 1250–1255.
14.
HemmerleinB., KuglerA., OzisikR., RingertR.H., RadzunH.J., and ThelenP. (2001). Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch, 439, 645–652.
15.
IacovelliR., SantiniD., RizzoM., FeliciA., SantoniM., VerzoniE., et al. (2015). Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Can Urol Assoc J, 9, 263–267.
16.
JiK., YeL., MasonM.D., and JiangW.G. (2013). The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (Review). Int J Mol Med, 32, 747–754.
17.
KochevarJ. (1990). Blockage of autonomous growth of ACHN cells by anti-renal cell carcinoma monoclonal antibody 5F4. Cancer Res, 50, 2968–2972.
18.
LaneB.R., and KattanM.W. (2005). Predicting outcomes in renal cell carcinoma. Curr Opin Urol, 15, 289–297.
19.
LeeJ.S., KimH.S., JungJ.J., ParkC.S., and LeeM.C. (2001). Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J Surg Oncol, 77, 55–60.
20.
LeeK.H., and KimJ.R. (2009). Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer. Oncol Res, 18, 107–116.
21.
LesK.A., NicholasR.W., RougraffB., WurtzD., VogelzangN.J., SimonM.A., et al. (2001). Local progression after operative treatment of metastatic kidney cancer. Clin Orthop Relat Res (390):206–211.
22.
LiH.L., HanL., ChenH.R., MengF., LiuQ.H., PanZ.Q., et al. (2015). PinX1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis by suppressing MMP-2 via NF-kappaB-dependent transcription. Oncotarget, 6, 21406–21420.
23.
LinY.W., LeeL.M., LeeW.J., ChuC.Y., TanP., YangY.C., et al. (2016). Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-kappaB-DNA-binding activity. J Pineal Res, 60, 277–290.
24.
LiuQ., ZhangG.W., ZhuC.Y., WeiJ.X., TianX., LiY., et al. (2016). Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: a case-control study and meta-analysis. Cancer Biomark, 16, 281–289.
25.
LokichJ. (1997). Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol, 20, 416–418.
26.
LuH., CaoX., ZhangH., SunG., FanG., ChenL., et al. (2014). Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways. Tumour Biol, 35, 9807–9813.
27.
MaldazysJ.D., and deKernionJ.B. (1986). Prognostic factors in metastatic renal carcinoma. J Urol, 136, 376–379.
28.
MinardiD., SantoniM., LucariniG., MazzucchelliR., BurattiniL., ContiA., et al. (2015). Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. Urol Oncol, 33, 113.e1–e7.
29.
MoseleG.R., CaggiariG., ScarpaR.M., DoriaC. (2016) Our experience in the treatment of vertebral metastases from renal cell carcinoma: a retrospective study. Minerva Urol Nefrol. [Epub ahead of print]; PubMed PMID: 27768024.
30.
MotzerR.J., MazumdarM., BacikJ., BergW., AmsterdamA., and FerraraJ. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17, 2530–2540.
31.
NadaO.H., AhmedN.S., and Abou GabalH.H. (2014). Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma. Diagn Pathol 9,72.
32.
OhbaK., MiyataY., MatsuoT., AsaiA., MitsunariK., ShidaY., et al. (2014). High expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma. Int J Clin Exp Pathol, 7, 3158–3165.
33.
OrdiJ., RomagosaC., TavassoliF.A., NogalesF., PalacinA., CondomE., et al. (2003). CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol, 27, 178–186.
34.
PanC.C., ChenP.C., and HoD.M. (2004). The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology, 45, 452–459.
35.
PattJ.C., and KneislJ.S. (2010). Metachronous presentation of metastasis from renal cell carcinoma: evaluation and management of spinal metastasis. Evid Based Spine Care J, 1, 75–82.
36.
RiniB.I., and SmallE.J. (2005). Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol, 23, 1028–1043.
37.
SaitohH. (1981). Distant metastasis of renal adenocarcinoma. Cancer, 48, 1487–1491.
38.
SantoniM., ContiA., ProcopioG., PortaC., IbrahimT., BarniS., et al. (2015). Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. J Exp Clin Cancer Res 34,10.
39.
ShippM.A., VijayaraghavanJ., SchmidtE.V., MastellerE.L., D'AdamioL., HershL.B., et al. (1989). Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (“enkephalinase”): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A, 86, 297–301.
40.
ShojiS., NakanoM., TomonagaT., KimH., HanaiK., UsuiY., et al. (2013). Value of metastin receptor immunohistochemistry in predicting metastasis after radical nephrectomy for pT1 clear cell renal cell carcinoma. Clin Exp Metastasis, 30, 607–614.
41.
ShojiS., TangX.Y., UmemuraS., ItohJ., TakekoshiS., ShimaM., et al. (2009). Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol, 55, 441–449.
42.
SmithE.M., KurshE.D., MakleyJ., and ResnickM.I. (1992). Treatment of osseous metastases secondary to renal cell carcinoma. J Urol, 148, 784–787.
43.
SohnS., ChungC.K., SohnM.J., ChangU.K., KimS.H., KimJ., et al. (2014). Stereotactic radiosurgery compared with external radiation therapy as a primary treatment in spine metastasis from renal cell carcinoma: a multicenter, matched-pair study. J Neurooncol, 119, 121–128.
44.
StrongC., YanamadalaV., KhannaA., WalcottB.P., NahedB.V., BorgesL.F., et al. (2013). Surgical treatment options and management strategies of metastatic renal cell carcinoma to the lumbar spinal nerve roots. J clin Neurosci, 20, 1546–1549.
45.
SwansonD.A., OrovanW.L., JohnsonD.E., and GiaccoG. (1981) Osseous metastases secondary to renal cell carcinoma. Urology, 18, 556–561.
46.
TaunkN.K., SprattD.E., BilskyM., and YamadaY. (2015). Spine radiosurgery in the management of renal cell carcinoma metastases. J Natl Compr Cancer Netw, 13, 801–809; quiz 809.
47.
TomitaK., KawaharaN., BabaH., TsuchiyaH., NagataS., and ToribatakeY. (1994). Total en bloc spondylectomy for solitary spinal metastases. Int Orthop, 18, 291–298.
48.
TomitaK., KawaharaN., KobayashiT., YoshidaA., MurakamiH., and AkamaruT. (2001) Surgical strategy for spinal metastases. Spine, 26, 298–306.
49.
TsuchiyaN., SatoK., AkaoT., KakinumaH., SasakiR., ShimodaN., et al. (2001). Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohoku J Exp Med, 195, 101–113.
50.
WangJ., RenY., GuoX., ChengH., YeY., QiJ., et al. (2015). Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma. Mol Med Rep, 11, 3585–3592.
51.
WilliamsR.D., ElliottA.Y., SteinN., and FraleyE.E. (1976). In vitro cultivation of human renal cell cancer. I. Establishment of cells in culture. In Vitro, 12, 623–627.
52.
XuL., TongR., CochranD.M., and JainR.K. (2005). Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res, 65, 5711–5719.
53.
YangB., AliS.Z., and RosenthalD.L. (2002). CD10 facilitates the diagnosis of metastatic renal cell carcinoma from primary adrenal cortical neoplasm in adrenal fine-needle aspiration. Diagn Cytopathol, 27, 149–152.
54.
YoshiokaK., OhnoY., HoriguchiY., OzuC., NamikiK., and TachibanaM. (2008). Effects of a KiSS-1 peptide, a metastasis suppressor gene, on the invasive ability of renal cell carcinoma cells through a modulation of a matrix metalloproteinase 2 expression. Life Sci, 83, 332–338.
55.
ZekriJ., AhmedN., ColemanR.E., and HancockB.W. (2001). The skeletal metastatic complications of renal cell carcinoma. Int J Oncol, 19, 379–382.
